General Mills R&D remained flat by 0.0% to $64.15M in Q1 2025 compared to the prior quarter. Year-over-year, this metric declined by 0.5%, from $64.45M to $64.15M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a 1.8% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $239.30M | $243.10M | $257.60M | $257.80M | $256.60M |
| YoY Change | — | +1.6% | +6.0% | +0.1% | -0.5% |